XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

During the third quarter of 2024, Chris Morabito, our Chief Medical Officer, adopted a Rule 10b5-1 trading arrangement for the sale of our common stock that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. This plan was adopted on September 25, 2024. Sales under the plan may begin on February 18, 2025 and no sales may be made after November 19, 2025. Pursuant to the plan, the aggregate number of options to be exercised, and the aggregate number of shares of common stock to be sold upon exercise of those options, is not to exceed 20,000.

None of our other directors or officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K) during the third quarter of 2024.

Chris Morabito  
Trading Arrangements, by Individual  
Name Chris Morabito
Title Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date September 25, 2024